Free Printable Doxium & Mosaspray Online Exam

1.

Mosaspray is ______________ kaya siguradong mabisa.

a)

Bioequivalent

b)

Comparable

c)

Therapeutically Equivalent

d)

Quality Branded Generic

2.

Mosaspray shows ____________ symptom control vs. other INCS.

a)

greater

b)

equal

c)

lesser

d)

best

3.

Use of INCS (Mosapray) is guidelines recommended by______________.

a)

A. PSO-HNS CPG

b)

B. ARIA Guidelines

c)

C. Both A&B

d)

D. None of the Above

4.

Mosaspray is sulit because _________.

a)

Cost-effective

b)

Covers 1 month use

c)

Provides savings vs Nasonex

d)

All options are correct

5.

How much is the savings the patient will enjoy using Mosaspray?

a)

Php 175

b)

Php 177

c)

Php 179

d)

None of the Above

6.

Mosaspray is safe because it has systemic bioavailability of __________

thereby limiting the risk for systemic adverse events.

A. B. C. D.

a)

<1%

b)

>1%

c)

<0.1%

d)

<0.01%

7.

The therapeutic equivalence study was done by ____________.

a)

Passali et al.

b)

Piotr Kuna et al.

c)

Sastre J et al.

d)

None of the above

8.

Proven efficacy study comparing symptom vs other INCS was done by____.

a)

Passali et al.

b)

Piotr Kuna et al

c)

Sastre J et al.

d)

None of the above

9.

Systemic bioavailability study was done by____.

a)

Passali et al.

b)

Piotr Kuna et al.

c)

Sastre J et al.

d)

None of the above

10.

Our 2020 tag line for Mosaspray is ________________.

a)

The Fitting Strategy for Nasal Allergy

b)

Allergy Mo, i-Mosaspray Mo

c)

Siguradong mabisa, safe at sulit

d)

Mosaspray is the only generic brand that is Therapeutically Equivalent to the Innovator.

11.

Doxium with its unique MOA with pleiotropic effect reduces ____________ (key message #1).

a)

A. vascular dysfunction

b)

B. vascular permeability

c)

C. both A & B

d)

D. none of the above

12.

Doxium significantly lowered the _________of the BRB (key message # 2).

a)

PVPR

b)

permeability

c)

complications

d)

dysfunction

13.

Doxium has proven ___________________ (key message #3)

a)

efficacy and tolerability profile

b)

efficacy

c)

savings

d)

safety

14.

Calcium dobesilate has been shown to ______________

B. C. D.

a)

Enhance nitric oxide

b)

Reduce capillary permeability and fragility

c)

Decrease blood hyperviscosity

d)

All options are correct

15.

Doxium taken _________ for 2 years showed a significant decrease in BRB leakage.

a)

500mg daily

b)

1g daily

c)

1.5g daily

d)

2g daily

16.

Doxium showed a significant decrease of ________ in BRB leakage.

a)

7.3%

b)

10%

c)

13.2%

d)

33%

17.

. Doxium is an effective treatment option to ______ the progression of Early-stage DR.

a)

slow

b)

treat

c)

stop

d)

end

18.

As per Vifor Pharma’s patient estimation in January 2016, there _______ million Doxium-treated patients.

a)

15

b)

40

c)

60

d)

50

19.

For how many years has Doxium been available for the patients?

a)

15

b)

40

c)

60

d)

50

20.

"Early ___________, Protects the Vision”

a)

Protection

b)

Intervention

c)

Detection

d)

Diagnosis

Doxium & Mosaspray Online Exam

Total questions: 20

Worksheet time: 3600secs

Similar Resources on Wayground